Veterinary Experts Join PetVivo Advisory Board
MINNEAPOLIS, MN May 26, 2016 PetVivo Holdings, Inc. (OTCPINK:PETV) an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for pets is very pleased to announce that John Wagoner and Brian Barnett, DVM have joined the PetVivo Veterinary Advisory Board. Mr. Wagoner and Dr. Barnett each bring the company more that twenty years of experience in the veterinary field.
Dr. Barnett is the owner and Chief of Staff at Randolph Animal Hospital as well as the newly opened Biscoe Pet Hospital, in the Greensboro/Winston-Salem, North Carolina Area. In addition, Dr. Barnett is a member of the Veterinary Management Group 21 (VMG-21) and serves as staff veterinarian for High Point, NC based Trone Marketing. Trone has a strong presence in the veterinary market, including marketing of the Greenies brand.
Dr. Barnett earned his Bachelors of Science in Zoology from Auburn University and Doctor of Veterinary Medicine from Auburn University’s College of Veterinary Medicine. In addition to his science and veterinary degrees, Dr. Barnett holds an MBA from Wake Forest’s Babcock School of Management.
John Wagoner brings extensive veterinary distribution management expertise to PetVivo. John is a co-founder of Boomerang Vet a data-based client communications service for Veterinary Hospitals located in Columbus, Ohio. In 2003, John founded, managed and grew CSC South Veterinary Supplies into the second largest veterinary distribution company in the Southeast region. In 2008, he sold CSC South Veterinary Supplies to Patterson Companies, Inc.
PetVivo’s CEO John Lai commented, “We are very pleased to have Mr. Wagoner & Dr. Barnett join our Veterinary Advisory Board. They each bring extensive veterinary industry experiences and unique skill sets to help guide us in commercializing our companion animal products.”
PetVivo’s lead product, Kush Canine, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is available for sale in limited quantities to key opinion leaders, with a targeted launch slated for later this year.
Dr. Barnett, who has had the opportunity to treat canine patients suffering from osteoarthritis with the Kush device at Randolph Animal Hospital, commented, “While my experience and observations of the Kush product are limited in duration, I believe this product has demonstrated effectiveness in treating canine OA joints. This product shows much potential in serving the very large arthritic canine population and is a product that can help grow my practice.”
You can learn more about Kush Canine and PetVivo by visiting the companies website at www.petvivo.com
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for commercial launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
PetVivo’s Corporate Presentation can be found here:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.